TearLab Corp  

(Public, NASDAQ:TEAR)   Watch this stock  
Find more results for TEAR
2.39
+0.02 (0.84%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.27 - 2.43
52 week 1.50 - 5.97
Open 2.35
Vol / Avg. 50,514.00/77,626.00
Mkt cap 81.44M
P/E     -
Div/yield     -
EPS -0.78
Shares 33.66M
Beta 2.91
Inst. own 37%
Aug 5, 2015
Q2 2015 Tearlab Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 7, 2015
Q1 2015 TearLab Corp Earnings Call
May 7, 2015
Q1 2015 Tearlab Corp Earnings Release
Mar 12, 2015
Q4 2014 TearLab Corp Earnings Call
Mar 12, 2015
Q4 2014 TearLab Corp Earnings Release
Mar 9, 2015
Tearlab Corp at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -151.04% -120.31%
Operating margin -149.24% -126.81%
EBITD margin - -111.91%
Return on average assets -95.42% -58.58%
Return on average equity -157.13% -72.16%
Employees 132 -
CDP Score - -

Address

Suite 200, 7360 Carroll Rd
SAN DIEGO, CA 92121
United States - Map
+1-858-4556006 (Phone)
+1-858-8120540 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). TearLab Research, Inc., its wholly owned subsidiary, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (i.e. glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. Its TearLab Osmolarity System enables the measurement of tear osmolarity in the doctor's office.

Officers and directors

Elias Vamvakas Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Joseph Jensen President, Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
William G. Dumencu Chief Financial Officer
Age: 60
Bio & Compensation  - Reuters
Raymond Kong Vice President - Sales
Bio & Compensation  - Reuters
Paul Smith Vice President - International
Age: 37
Bio & Compensation  - Reuters
Duane Morrison Vice President - Business Development
Age: 51
Bio & Compensation  - Reuters
Anthony E. Altig Independent Director
Age: 59
Bio & Compensation  - Reuters
Thomas N. Davidson Jr. Independent Director
Age: 55
Bio & Compensation  - Reuters
Adrienne L. Graves Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Paul M. Karpecki Independent Director
Age: 47
Bio & Compensation  - Reuters